Silvercrest Asset Management Group LLC Grows Stock Holdings in Phreesia, Inc. (NYSE:PHR)

Silvercrest Asset Management Group LLC lifted its position in Phreesia, Inc. (NYSE:PHR - Free Report) by 31.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 394,352 shares of the company's stock after buying an additional 93,349 shares during the quarter. Silvercrest Asset Management Group LLC owned about 0.68% of Phreesia worth $9,922,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Phreesia by 10.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 493,448 shares of the company's stock valued at $12,415,000 after purchasing an additional 46,209 shares during the period. Wesbanco Bank Inc. raised its stake in Phreesia by 76.9% in the 4th quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company's stock worth $1,157,000 after purchasing an additional 20,000 shares in the last quarter. Barclays PLC raised its position in shares of Phreesia by 83.6% in the third quarter. Barclays PLC now owns 94,929 shares of the company's stock valued at $2,163,000 after buying an additional 43,225 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Phreesia in the fourth quarter valued at approximately $377,000. Finally, M&T Bank Corp grew its position in Phreesia by 56.4% during the fourth quarter. M&T Bank Corp now owns 54,939 shares of the company's stock worth $1,382,000 after buying an additional 19,812 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Price Performance

Shares of PHR stock traded down $0.23 on Friday, reaching $24.11. The company's stock had a trading volume of 40,763 shares, compared to its average volume of 460,533. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53. The company has a market capitalization of $1.43 billion, a P/E ratio of -16.40 and a beta of 0.74. The stock's 50 day simple moving average is $25.24 and its 200-day simple moving average is $25.12.

Insider Activity

In other news, CFO Balaji Gandhi sold 8,045 shares of the firm's stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total value of $191,873.25. Following the completion of the sale, the chief financial officer now directly owns 108,411 shares of the company's stock, valued at approximately $2,585,602.35. This trade represents a 6.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Evan Roberts sold 7,233 shares of the company's stock in a transaction that occurred on Tuesday, April 8th. The stock was sold at an average price of $23.85, for a total value of $172,507.05. Following the completion of the sale, the chief operating officer now owns 776,652 shares in the company, valued at $18,523,150.20. The trade was a 0.92% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 42,474 shares of company stock valued at $1,023,208. 5.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

PHR has been the topic of a number of recent analyst reports. DA Davidson decreased their price objective on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Piper Sandler reissued an "overweight" rating and set a $33.00 price target (up previously from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. KeyCorp reduced their price objective on Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. Needham & Company LLC restated a "buy" rating and issued a $29.00 target price on shares of Phreesia in a research report on Thursday, March 13th. Finally, Canaccord Genuity Group increased their price target on Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $31.33.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.